The European Commission’s decision will make the product the first disease-modifying treatment to be available for the condition in Europe. The European Commission has approved Teizeild (teplizumab) as the first…
Sanofi announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review its supplemental Biologics License Application (sBLA) for Tzield (teplizumab-mzwv) targeting young children with stage 2…
Sanofi could be months away from wider US approval for Tzield, its first-in-class drug for delaying the progression of type 1 diabetes (T1D), in children as young as one. The…
Toronto, February 20, 2024 /CNW/ – JDRF and Sanofi Canada have announced a partnership aimed at raising awareness of the chronic autoimmune disease type 1 diabetes (T1D) and the role…